PANC-1人胰腺癌细胞

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1142

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line namePANC-1
SynonymsPanc-1; PANC.1; Panc 1; PanC1; Panc1; PANC1; Panc-1-P
AccessionBTCC-1142
Resource Identification InitiativeTo cite this cell line use: PANC-1 (BTCC-1142)
CommentsPart of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: ENCODE project common cell types; tier 3.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Doubling time: 25.83 +- 2.03 hours (PubMed=25394408); 21 +- 1.6 hours (PubMed=21515691); 52 hours (CLS=300228); ~42 hours (DSMZ=ACC-783); ~32 hours (PBCF); 15.02 hours (GrayJW panel).
Karyotypic information: Has lost chromosome Y.
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
Caution: Additional TP53 mutation in c.815T>C indicated incorrectly in PubMed=1630814.
Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
Sequence variations
HLA typingSource: PubMed=9023415
Class I
HLA-AA*02:01,11:01
HLA-BB*01,38
HLA-CC*03,12

Source: PubMed=18575732
Class I
HLA-AA*02,11
HLA-BB*01,38
HLA-CC*03,12

Source: PubMed=26589293
Class I
HLA-AA*02:01,11:01
HLA-BB*38:01,38:01
HLA-CC*12:03,12:03
Class II
HLA-DQDQB1*06:07,06:07
HLA-DRDRB1*11:20,14:43

Source: CLS=300228
Class I
HLA-AA*02:01:01,11:01:01
HLA-BB*38:01:01
HLA-CC*12:03:01
Class II
HLA-DPDPB1*12:01:02G,04:02:01G
HLA-DQDQA1*01:03:01

DQB1*06:03:01
HLA-DRDRB1*13:01:01
Genome ancestrySource: PubMed=30894373

Origin% genome


African2.26
Native American0
East Asian, North2.09
East Asian, South0
South Asian0
European, North60
European, South35.65
DiseasePancreatic ductal adenocarcinoma (NCIt: C9120)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:



CVCL_1778 (1.1B4)CVCL_2257 (1.1E7)CVCL_2259 (1.4E7)
CVCL_3002 (KP-1N)CVCL_A4BT (PANC-1 Ecadherin EmGFP)CVCL_WL48 (PANC-1-Cas9-554)
CVCL_WL49 (PANC-1-Cas9-555)CVCL_WL50 (PANC-1-Cas9-556)CVCL_WL51 (PANC-1-Cas9-557)
CVCL_WL52 (PANC-1-Cas9-558)CVCL_WL53 (PANC-1-Cas9-559)CVCL_VQ69 (Panc-1-CTC)
CVCL_A4BU (PANC-1-Luc2)CVCL_C0WS (PANC-1/Gem)CVCL_WS13 (PANC-1RG7)
CVCL_0Q68 (Panc1-MUC1)

Sex of cellMale
Age at sampling56Y
CategoryCancer cell line
STR profileSource(s): AddexBio; ATCC; CCRID; CLS; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX
CSF1PO10,12
D1S165612,14
D2S44110,14
D2S133823,24
D3S135817
D5S81811,13
D6S104311,12
D7S8208,10
D8S117914,15
D10S124814
D12S39122
D13S31711
D16S53911
D18S5112
D19S43311,16
D21S1128
D22S104516
FGA21
Penta D14
Penta E7,14
TH017,8
TPOX8,11
vWA15

Run an STR similarity search on this cell line
Web pageshttps://en.wikipedia.org/wiki/PANC-1
https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/PANC-1.html
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=PANC-1
https://www.synapse.org/#!Synapse:syn31544566
http://genome.ucsc.edu/ENCODE/protocols/cell/human/PANC-1_Myers_protocol.pdf
https://strap.nci.nih.gov/celline_detail.php?sample_id=65
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-179.html
https://tcpaportal.org/mclp/
https://www.phe-culturecollections.org.uk/media/120309/panc-1-cell-line-profile.pdf
Publications

PubMed=1140870; DOI=10.1002/ijc.2910150505
Lieber M.M., Mazzetta J., Nelson-Rees W.A., Kaplan M., Todaro G.J.
Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas.
Int. J. Cancer 15:741-747(1975)

PubMed=6435863
Chang B.K., Black O. Jr., Gutman R.
Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Cancer Res. 44:5100-5104(1984)

PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

PubMed=1630814
Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 7:1503-1511(1992)

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x
Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.
K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
Jpn. J. Cancer Res. 85:1005-1014(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7
Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.
Gastroenterology 106:1645-1651(1994)

PubMed=8286197; DOI=10.1038/bjc.1994.24
Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.
Br. J. Cancer 69:144-151(1994)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::aid-ijc1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::aid-ijc1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)

PubMed=15367885; DOI=10.1097/00006676-200410000-00004
Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Pancreas 29:193-203(2004)

PubMed=15688027; DOI=10.1038/sj.onc.1208383
Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Oncogene 24:1794-1801(2005)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer Res. 66:7920-7928(2006)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=18575732; DOI=10.3892/or.20.1.155
Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Oncol. Rep. 20:155-163(2008)

CLPUB00416
Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

DOI=10.4172/jpb.1000057
Masayo Y., Kiyonaga F., Koji K., Setsuo H., Tadashi K.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinformatics 2:1-18(2009)

PubMed=19077451; DOI=10.1159/000178871
Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.
Genome-wide analysis of pancreatic cancer using microarray-based techniques.
Pancreatology 9:13-24(2009)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=21515691; DOI=10.1074/jbc.M111.226795
McCluskey J.T., Hamid M., Hong G.-P., McClenaghan N.H., Gomis R., Flatt P.R.
Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion.
J. Biol. Chem. 286:21982-21992(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25394408; DOI=10.3892/or.2014.3599
Wang C.-F., Zhang W.-W., Fu M.-J., Yang A.-Q., Huang H.-H., Xie J.-M.
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression.
Oncol. Rep. 33:383-390(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30156359; DOI=10.1111/cas.13783
Sato T., Muramatsu T., Tanabe M., Inazawa J.
Identification and characterization of TGFBI in circulating tumor cell subline from pancreatic cancer cell line.
Cancer Sci. 109:3623-3633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31037374; DOI=10.1007/s00216-019-01814-1
Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.
Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.
Anal. Bioanal. Chem. 411:6319-6328(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32058723; DOI=10.1021/acs.jproteome.9b00840
Tan Z., Zhu J., Stemmer P.M., Sun L., Yang Z., Schultz K., Gaffrey M.J., Cesnik A.J., Yi X., Hao X.-H., Shortreed M.R., Shi T., Lubman D.M.
Comprehensive detection of single amino acid variants and evaluation of their deleterious potential in a PANC-1 cell line.
J. Proteome Res. 19:1635-1646(2020)

PubMed=32782605; DOI=10.3892/ol.2020.11825
Takagi K., Imura J., Shimomura A., Noguchi A., Minamisaka T., Tanaka S., Nishida T., Hatta H., Nakajima T.
Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32.
Oncol. Lett. 20:2888-2896(2020)

Cross-references
Cell line databases/resourcesCLO; CLO_0008381
CLO; CLO_0050102
MCCL; MCC:0000378
CLDB; cl3872
CLDB; cl3873
CLDB; cl3874
CCRID; 1101HUM-PUMC000023
CCRID; 3101HUMSCSP535
CCRID; 3101HUMTCHu98
CCRID; 4201HUM-CCTCC00309
CCRID; 5301HUM-KCB08009YJ
Cell_Model_Passport; SIDM00610
CGH-DB; 180-1
CGH-DB; 9267-4
DepMap; ACH-000164
DSMZCellDive; ACC-783
LINCS_LDP; LCL-1726
Lonza; 818
SKY/M-FISH/CGH; 2001
TOKU-E; 2865
Anatomy/cell type resourcesBCGO; BCGO_0000122
BTO; BTO:0000304
Biological sample resources4DN; 4DNSRDQPS1VU
BioSample; SAMN01821587
BioSample; SAMN03472068
BioSample; SAMN05292439
BioSample; SAMN10987682
ENCODE; ENCBS101NPD
ENCODE; ENCBS314FVF
ENCODE; ENCBS397PLZ
ENCODE; ENCBS399ENC
ENCODE; ENCBS425ENC
ENCODE; ENCBS465AAA
ENCODE; ENCBS466AAA
ENCODE; ENCBS467AAA
ENCODE; ENCBS470AAA
ENCODE; ENCBS492WPY
ENCODE; ENCBS556WYR
ENCODE; ENCBS729QZR
ENCODE; ENCBS761TKL
ENCODE; ENCBS808TSD
ENCODE; ENCBS830QHD
ENCODE; ENCBS945URM
Cell line collections (Providers)AddexBio; C0018010/4923
ATCC; CRL-1469
BCRC; 60284
BCRJ; 0201
CCTCC; GDC0309
CLS; 300228
DSMZ; ACC-783
ECACC; 87092802
IBRC; C10156
IZSLER; BS TCL 49
KCB; KCB 200788YJ
KCB; KCB 200809YJ
KCLB; 21469
NCBI_Iran; C556
RCB; RCB2095
TKG; TKG 0606
Chemistry resourcesChEMBL-Cells; CHEMBL3307545
ChEMBL-Targets; CHEMBL614139
PharmacoDB; PANC1_1246_2019
PubChem_Cell_line; CVCL_0480
Encyclopedic resourcesWikidata; Q54937550
Experimental variables resourcesEFO; EFO_0002713

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部